Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Mesoblast Logo
Mesoblast Growth Score
91
CB Rank
20753
Heat Score
69
Mesoblast is a medicine company that develops biologic products for the broad field of regenerative medicine.
Founded
obfuscation
PublicPost-IPO Debt Melbourne, Victoria, Australia51-100 www.mesoblast.com
Biotechnology
Health Care
Health Diagnostics
Overview

Mesoblast
Total Funding
obfuscation
Growth Score
91
Heat Score
69

Total Funding
obfuscation
obfuscation
Post-IPO Debt raised
obfuscation
Growth Score91
-6 pts
in past quarter
Heat Score 69
2 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Mesoblast

CB Rank
20753
Mesoblast is a medicine company that develops biologic products for the broad field of regenerative medicine.
Founded
obfuscation
PublicPost-IPO Debt Melbourne, Victoria, Australia51-100 www.mesoblast.com
Biotechnology
Health Care
Health Diagnostics

Funding Rounds

Post-IPO Debt
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation

Key People

Details

Legal Name Mesoblast Ltd.
Operating Status Active
Number of Exits 
obfuscation
Stock Symbol  ASX:MSB
Company Type For Profit
Founders  Michael Schuster, Silviu Itescu
About the Company

Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's patented Mesenchymal Precursor Cell (MPC) technology is being developed for an extensive range of major clinical diseases, including inflammatory and immunologic conditions of the joints and lungs, diabetes, and kidney disease, orthopedic

spine conditions, and cardiovascular disorders.

Phone Number (212) 880-2060
Contact Email info@mesoblast.com
Predictions & Insights

Growth Insight

See this Growth Insight
Mesoblast is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

Remestemcel-L for steroid-refractory acute graft versus host disease (acute GVHD) in children
An allogeneic cellular medicine for treating steroid-refractory acute GVHD in pediatric patients.
Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection
A cellular therapy using mesenchymal lineage cells to treat moderate to severe ARDS caused by COVID-19 infection.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 11
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - Mesoblast Logo
Post-IPO Debt - Mesoblast
1
obfuscation
Gregory GeorgePost-IPO Debt
obfuscation
Post-IPO Debt - Mesoblast Logo
Post-IPO Debt - Mesoblast
1
obfuscation
Gregory GeorgePost-IPO Debt
obfuscation
Post-IPO Debt - Mesoblast Logo
Post-IPO Debt - Mesoblast
1
obfuscation
Gregory GeorgePost-IPO Debt
obfuscation
Post-IPO Debt - Mesoblast Logo
Post-IPO Debt - Mesoblast
1
obfuscation
Gregory GeorgePost-IPO Debt
obfuscation
Post-IPO Debt - Mesoblast Logo
Post-IPO Debt - Mesoblast
1
obfuscation
Gregory GeorgePost-IPO Debt

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 11
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - Mesoblast Logo
Post-IPO Debt - Mesoblast
1
obfuscation
Gregory GeorgePost-IPO Debt
obfuscation
Post-IPO Debt - Mesoblast Logo
Post-IPO Debt - Mesoblast
1
obfuscation
Gregory GeorgePost-IPO Debt
obfuscation
Post-IPO Debt - Mesoblast Logo
Post-IPO Debt - Mesoblast
1
obfuscation
Gregory GeorgePost-IPO Debt
obfuscation
Post-IPO Debt - Mesoblast Logo
Post-IPO Debt - Mesoblast
1
obfuscation
Gregory GeorgePost-IPO Debt
obfuscation
Post-IPO Debt - Mesoblast Logo
Post-IPO Debt - Mesoblast
1
obfuscation
Gregory GeorgePost-IPO Debt

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Photo of Gregory George
Gregory George
Yes
Post-IPO Debt - Mesoblast Logo
Post-IPO Debt - Mesoblast
—
Photo of Gregory George
Gregory George
Yes
Post-IPO Debt - Mesoblast Logo
Post-IPO Debt - Mesoblast
—
Photo of Gregory George
Gregory George
Yes
Post-IPO Debt - Mesoblast Logo
Post-IPO Debt - Mesoblast
—
Photo of Gregory George
Gregory George
Yes
Post-IPO Debt - Mesoblast Logo
Post-IPO Debt - Mesoblast
—
Photo of Gregory George
Gregory George
Yes
Post-IPO Debt - Mesoblast Logo
Post-IPO Debt - Mesoblast
—

Investments

Number of Investments 1
Number of Exits 
obfuscation
Number of Acquisitions 1
See investment data for this company, with details on deal size, industry, stage, and more.
Announced Date  
Organization Name  
Lead Investor  
Funding Round  
Money Raised  
obfuscation
Osiris Therapeutics Logo
Osiris Therapeutics
Yes
Post-IPO Equity - Osiris Therapeutics Logo
Post-IPO Equity - Osiris Therapeutics
obfuscation
obfuscation
Osiris Therapeutics Logo
Osiris Therapeutics
Yes
Post-IPO Equity - Osiris Therapeutics Logo
Post-IPO Equity - Osiris Therapeutics
obfuscation
obfuscation
Osiris Therapeutics Logo
Osiris Therapeutics
Yes
Post-IPO Equity - Osiris Therapeutics Logo
Post-IPO Equity - Osiris Therapeutics
obfuscation
obfuscation
Osiris Therapeutics Logo
Osiris Therapeutics
Yes
Post-IPO Equity - Osiris Therapeutics Logo
Post-IPO Equity - Osiris Therapeutics
obfuscation
obfuscation
Osiris Therapeutics Logo
Osiris Therapeutics
Yes
Post-IPO Equity - Osiris Therapeutics Logo
Post-IPO Equity - Osiris Therapeutics
obfuscation

Investment Breakdown

Number of Investments 1
Number of Exits 
obfuscation
Number of Acquisitions 1
See investment data for this company, with details on deal size, industry, stage, and more.
Announced Date  
Organization Name  
Lead Investor  
Funding Round  
Money Raised  
obfuscation
Osiris Therapeutics Logo
Osiris Therapeutics
Yes
Post-IPO Equity - Osiris Therapeutics Logo
Post-IPO Equity - Osiris Therapeutics
obfuscation
obfuscation
Osiris Therapeutics Logo
Osiris Therapeutics
Yes
Post-IPO Equity - Osiris Therapeutics Logo
Post-IPO Equity - Osiris Therapeutics
obfuscation
obfuscation
Osiris Therapeutics Logo
Osiris Therapeutics
Yes
Post-IPO Equity - Osiris Therapeutics Logo
Post-IPO Equity - Osiris Therapeutics
obfuscation
obfuscation
Osiris Therapeutics Logo
Osiris Therapeutics
Yes
Post-IPO Equity - Osiris Therapeutics Logo
Post-IPO Equity - Osiris Therapeutics
obfuscation
obfuscation
Osiris Therapeutics Logo
Osiris Therapeutics
Yes
Post-IPO Equity - Osiris Therapeutics Logo
Post-IPO Equity - Osiris Therapeutics
obfuscation
Market Intelligence
People
View Profiles & Contacts
Headcount 51-100 Employee Profiles 8 Board Members and Advisors 2 Contacts 72

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jul 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 26, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 25, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 25, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

2,489
-19.81%
 in past month

Interest Signals

TopicSurge Score
Reddit Logo
Reddit
100
Capital Injection Logo
Capital Injection
90
Buyer Centricity Logo
Buyer Centricity
90

Actively Used Products

13Mesoblast uses 13 technology products and services including HTML5, Bootstrap, and  Cloudflare CDN, according to G2 Stack.

Active Website Tech Count

17Mesoblast is actively using 17 technologies for its website, according to BuiltWith. These include U.S. Server Location, DNSSEC, and  Euro.

Total IP

67The intellectual property of Mesoblast includes 57 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, Mesoblast has registered 10 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Mesoblast's headquarters? Mesoblast is located in Melbourne, Victoria, Australia.Who invested in Mesoblast? Mesoblast has 4 investors including Gregory George and  Gregory George.When was the last funding round for Mesoblast? Mesoblast closed its last funding round on
obfuscation
from a Post-IPO Debt round.Who are Mesoblast's competitors? Alternatives and possible competitors to Mesoblast may include StemInov, Nuwacell, and  Cell2Cure.How much funding has Mesoblast raised to date? Mesoblast has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(35d1611 1)
|